Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?
Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo